https://www.selleckchem.com/products/ak-7.html The relative abundance of functional groups of chemoheterotrophy, aerobic chemoheterotrophy, as well as that connected to N cycles also increased, which implied the improvement of the pollution removal efficiency. Meanwhile, the copy number of α-amylase and endoglucanase increased significantly in Column 1 with the addition of B. subtilis, which offers further support for a hydrolase-induced reduction of polysaccharides and the efficiency of B. subtilis on bio-clogging alleviation. The results showed that B. subtilis addition is an effective and safe solution to control the bio-clogging for CWs. However, further research about long-term effect assessment and dosing strategy optimization should be conducted.This study was undertaken to assess the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs), mainly liraglutide and exenatide, on glycemic control and anthropometric profiles to see if they are effective in treating patients with non-alcoholic fatty liver disease (NAFLD) and type-2 diabetes mellitus (T2DM). We searched PubMed, Embase, Scopus, Web of Science (WOS), and Cochrane Library databases to identify all the randomized clinical trials (RCTs) up to August 23, 2020. Heterogeneity of the included studies was evaluated using Cochrane's Q test and the I2 statistic. Moreover, a random-effects model was used to pool the weighted mean differences (WMDs) and their 95% confidence intervals (CIs). Nine articles (12 studies) comprising a total of 780 participants aged 40-56 were finally selected. GLP-1RAs intake significantly reduced body mass index (BMI) (WMD -1.57, 95%CI; -2.74, -0.39), waist-circumference (WC) (WMD -4.14, 95%CI; -7.09, -1.19), body weight (WMD -4.20, 95%CI; -8.15, -0.25) among the body mass indices. Additionally, GLP-1RAs leads to lower postprandial plasma glucose (PPG) levels (WMD -25.73 mg/dl, 95%CI; -32.71, -18.75). We also found that GLP-1RAs intake has no significant effect on the waist-